You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
西藏藥業(600211.SH)2019年度淨利升44.86%至3.12億元 擬10轉4派10.6元
格隆匯 03-12 20:14

格隆匯3月12日丨西藏藥業(600211.SH)發佈2019年年度報告,實現營業收入12.56億元,同比增長22.20%;歸屬於上市公司股東的淨利潤3.12億元,同比增長44.86%;歸屬於上市公司股東的扣除非經常性損益的淨利潤3.05億元,同比增長99.29%;基本每股收益1.75元;擬每10股派發現金10.60元(含税),資本公積金每10股轉增4股。

報告期內,公司業績穩步增長,全年主營業務收入12.49億元,心血管領域產品新活素、依姆多、諾迪康膠囊佔比91.15%,其中新活素佔全年銷售收入的65.22%,新活素銷售收入較去年同期增長46.78%。

報告期內,新活素產品繼2017年被納入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2017年版)》乙類範圍後,近兩年銷量大幅上升;2019年11月,新活素再次被納入《國家基本醫療保險、工傷保險和生育保險藥品目錄》(2019年版)乙類範圍,中長期將有利於新活素市場份額的擴大、市場佈局的拓展,對公司今後的銷售增長和長遠發展產生積極作用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account